Propranolol

( DrugBank: Propranolol / KEGG DRUG: Propranolol )


5 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease1
158Tuberous sclerosis1
167Marfan syndrome1
IDDisease name (Link within this page)Number of trials
227Osler disease1
278Huge lymphatic malformation with cervicofacial lesion1

6. Parkinson disease


Clinical trials : 2,307Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

158. Tuberous sclerosis


Clinical trials : 112Drugs : 71 - (DrugBank : 19) / Drug target genes : 35 - Drug target pathways : 118 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

167. Marfan syndrome


Clinical trials : 21Drugs : 40 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 50 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

227. Osler disease


Clinical trials : 56Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

278. Huge lymphatic malformation with cervicofacial lesion


Clinical trials : 19Drugs : 22 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 63 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries